These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 2065844

  • 21. The role of high-frequency audiometry in early detection of ototoxicity.
    Dreschler WA, vd Hulst RJ, Tange RA, Urbanus NA.
    Audiology; 1985; 24(6):387-95. PubMed ID: 4084111
    [Abstract] [Full Text] [Related]

  • 22. Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
    Skalleberg J, Solheim O, Fosså SD, Småstuen MC, Osnes T, Gundersen POM, Bunne M.
    Gynecol Oncol; 2017 Apr; 145(1):148-153. PubMed ID: 28202195
    [Abstract] [Full Text] [Related]

  • 23. Ototoxicity of cisplatin in gynaecological cancer patients.
    Laurell G, Borg E.
    Scand Audiol; 1988 Apr; 17(4):241-7. PubMed ID: 3232027
    [Abstract] [Full Text] [Related]

  • 24. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
    Biró K.
    Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
    [Abstract] [Full Text] [Related]

  • 25. Audiometric monitoring of cis-platinum ototoxicity.
    Brown RL, Nuss RC, Patterson R, Irey J.
    Gynecol Oncol; 1983 Oct; 16(2):254-62. PubMed ID: 6685094
    [Abstract] [Full Text] [Related]

  • 26. Evaluation of the hearing loss associated with cis-platinum treatment by high-frequency audiometry.
    Kujansuu E, Rahko T, Punnonen R, Karma P.
    Gynecol Oncol; 1989 Jun; 33(3):321-2. PubMed ID: 2722056
    [Abstract] [Full Text] [Related]

  • 27. [Ototoxic side effects in patients with ovarian cancer treated with cisplatin].
    Behling H, Spieske C, Krafft W.
    Zentralbl Gynakol; 1988 Jun; 110(5):277-82. PubMed ID: 3376611
    [Abstract] [Full Text] [Related]

  • 28. Audiometric test criteria in the detection of cisplatin ototoxicity.
    Simpson TH, Schwan SA, Rintelmann WF.
    J Am Acad Audiol; 1992 May; 3(3):176-85. PubMed ID: 1581592
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
    Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O.
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Ototoxicity from cisplatin therapy in childhood cancer.
    Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL.
    J Pediatr Hematol Oncol; 2007 Jun; 29(6):355-60. PubMed ID: 17551394
    [Abstract] [Full Text] [Related]

  • 33. Cisplatin ototoxicity: the importance of baseline audiometry.
    Nagy JL, Adelstein DJ, Newman CW, Rybicki LA, Rice TW, Lavertu P.
    Am J Clin Oncol; 1999 Jun; 22(3):305-8. PubMed ID: 10362343
    [Abstract] [Full Text] [Related]

  • 34. High-frequency monitoring for early detection of cisplatin ototoxicity.
    Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, Bagby GC.
    Arch Otolaryngol Head Neck Surg; 1993 Jun; 119(6):661-6. PubMed ID: 8499098
    [Abstract] [Full Text] [Related]

  • 35. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
    Biro K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, Bodrogi I.
    Oncology; 2006 Jun; 70(3):177-84. PubMed ID: 16757924
    [Abstract] [Full Text] [Related]

  • 36. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
    Caballero M, Mackers P, Reig O, Buxo E, Navarrete P, Blanch JL, Grau JJ.
    Oncology; 2017 Jun; 93(2):75-82. PubMed ID: 28511189
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
    Freilich RJ, Kraus DH, Budnick AS, Bayer LA, Finlay JL.
    Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
    [Abstract] [Full Text] [Related]

  • 40. Extended high-frequency ototoxicity induced by the first administration of cisplatin.
    Sakamoto M, Kaga K, Kamio T.
    Otolaryngol Head Neck Surg; 2000 Jun; 122(6):828-33. PubMed ID: 10828794
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.